Investors
A MESSAGE FROM OUR CEO
”Ensuring the RA trial stays on track is key, but there are other diseases where activating the melanokortin system can potentially make a big impact.”
-
April 24, 2025 RegulatoryNotice of annual general meeting in SynAct Pharma AB
-
April 23, 2025 Non RegulatorySynAct receives Notice of Allowance for grant of US Patent covering resomelagon (AP1189) combination therapy
-
April 16, 2025 Non RegulatorySynAct Pharma to participate at BIO International Convention in Boston June 16-19